news
FDA approves Abecma, the first cell-based gene therapy for adults with multiple myeloma
Abecma (idecabtagene vicleucel) was approved for adults with relapsed or refractory myeloma based on its 72 percent overall response rate in a trial.
List view / Grid view
Celgene Corporation
news
Chinese ABRAXANE® supply expected to be disrupted
The marketing agent for China, BeiGene, announced the China National Medical Products Administration (NMPA) suspended the importation, sales and use of ABRAXANE.
news
Bristol-Myers Squibb completes acquisition of Celgene
After regulatory approval, Bristol-Myers Squibb has announced its successful acquisition of Celgene, completing the merger.
news
Ozanimod successful in clinical trials for multiple sclerosis
The findings from the two pivotal phase 3 trials pave the way for ozanimod to enter the New Drug Approval process with the FDA...
news
FDA approves new targeted treatment for acute myeloid leukemia
The U.S. Food and Drug Administration has granted the approval of Idhifa to Celgene Corporation and RealTime IDH2 Assay to Abbott Laboratories...
